Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505. https://doi.org/10.1136/bmj.k2505. Erratum in: BMJ. 2018; 363:k4413.

Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2014;134(4):774–82. https://doi.org/10.1016/j.thromres.2014.06.020.

Article  CAS  PubMed  Google Scholar 

Pollack CV Jr. Evidence supporting idarucizumab for the reversal of dabigatran. Am J Emerg Med. 2016;34(11S):33–8. https://doi.org/10.1016/j.ajem.2016.09.051.

Article  PubMed  Google Scholar 

Milioglou I, Farmakis I, Neudeker M, Hussain Z, Guha A, Giannakoulas G, Kotoula V, Papaioannou M. Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. J Thromb Thrombol. 2021;52(4):1137–50. https://doi.org/10.1007/s11239-021-02480-w.

Article  CAS  Google Scholar 

Sartori M, Cosmi B. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy. J Thromb Thrombol. 2018;45(3):345–52. https://doi.org/10.1007/s11239-018-1617-2.

Article  CAS  Google Scholar 

Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, Molina CA, Bereczki D, Toni D, Seiffge DJ, Tanne D, Sandset EC, Tsivgoulis G, Christensen H, Beyer-Westendorf J, Coutinho JM, Crowther M, Verhamme P, Amarenco P, Roine RO, Mikulik R, Lemmens R, Veltkamp R, Middeldorp S, Robinson TG, Milling TJ Jr, Tedim-Cruz V, Lang W, Himmelmann A, Ladenvall P, Knutsson M, Ekholm E, Law A, Taylor A, Karyakina T, Xu L, Tsiplova K, Poli S, Kallmünzer B, Gumbinger C, Shoamanesh A, ANNEXA-I Investigators. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. N Engl J Med. 2024;390(19):1745–55. https://doi.org/10.1056/NEJMoa2313040.

Article  CAS  PubMed  Google Scholar 

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https://doi.org/10.1136/bmj.n160.

Article  PubMed  PubMed Central  Google Scholar 

Franco JVA, Garrote V, Vietto V, Escobar Liquitay CM, Solà I. Search strategies (filters) to identify systematic reviews in MEDLINE and embase. Cochrane Database Syst Rev. 2020;2020(7):MR000054. https://doi.org/10.1002/14651858.MR000054.

Article  PubMed Central  Google Scholar 

McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–6. https://doi.org/10.1016/j.jclinepi.2016.01.021.

Article  PubMed  Google Scholar 

Büchter RB, Weise A, Pieper D. Development, testing and use of data extraction forms in systematic reviews: a review of methodological guidance. BMC Med Res Methodol. 2020;20(1):259. https://doi.org/10.1186/s12874-020-01143-3.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Article  PubMed  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.

Article  PubMed  PubMed Central  Google Scholar 

Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B, Coleman CI. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care. 2022;26(1):180. https://doi.org/10.1186/s13054-022-04043-8.

Article  PubMed  PubMed Central  Google Scholar 

Parsels KA, Seabury RW, Zyck S, Miller CD, Krishnamurthy S, Darko W, Probst LA, Latorre JG, Cwikla GM, Feldman EA. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis. Am J Emerg Med. 2022. https://doi.org/10.1016/j.ajem.2022.02.036.

Article  PubMed  Google Scholar 

Keinath JJ, Lekura J, Hauser CD, Bajwa MK, Bloome ME, Kalus JS, Jones MC. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds. J Thromb Thrombol. 2023;56(2):315–22. https://doi.org/10.1007/s11239-023-02840-8.

Article  CAS  Google Scholar 

Sutton SS, Magagnoli J, Cummings TH, Dettling T, Lovelace B, Christoph MJ, Hardin JW. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis. 2023;56(1):137–146. https://doi.org/10.1007/s11239-023-02820-y. Erratum in: J Thromb Thrombolysis. 2023.

Cohen AT, Lewis M, Connor A, Connolly SJ, Yue P, Curnutte J, Alikhan R, MacCallum P, Tan J, Green L. Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. J Am Coll Emerg Phys Open. 2022;3(2):e12655. https://doi.org/10.1002/emp2.12655.

Article  Google Scholar 

Barra ME, Das AS, Hayes BD, Rosenthal ES, Rosovsky RP, Fuh L, Patel AB, Goldstein JN, Roberts RJ. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost. 2020;18(7):1637–47. https://doi.org/10.1111/jth.14838.

Article  CAS  PubMed  Google Scholar 

Pham H, Medford WG, Horst S, Levesque M, Ragoonanan D, Price C, Colbassani H, Piper K, Chastain K. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. Am J Emerg Med. 2022;55:38–44. https://doi.org/10.1016/j.ajem.2022.02.029.

Article  PubMed  Google Scholar 

Siepen BM, Polymeris A, Shoamanesh A, Connolly S, Steiner T, Poli S, Lemmens R, Goeldlin MB, Müller M, Branca M, Rauch J, Meinel T, Kaesmacher J, Z’Graggen W, Arnold M, Fischer U, Peters N, Engelter ST, Lyrer P, Seiffge D. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors: individual patient data analysis of ANNEXA-4 and TICH-NOAC. Int J Stroke. 2024. https://doi.org/10.1177/17474930241230209.

Article  PubMed  Google Scholar 

Schmidt LE, Hinton MS, Martin ND. Real-world reversal of factor Xa inhibition in the setting of major life-threatening bleeding or urgent surgery. J Pharm Pract. 2024;37(1):74–9. https://doi.org/10.1177/08971900221125516.

Article  PubMed  Google Scholar 

Oh ES, Schulze P, Diaz F, Shah K, Rios J, Silverman ME. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage. Am J Emerg Med. 2023;64:74–7. https://doi.org/10.1016/j.ajem.2022.11.023.

Article  PubMed  Google Scholar 

Troyer C, Nguyen W, Xie A, Wimer D. Retrospective review of Andexanet Alfa versus 4-factor prothrombin complex concentrate for reversal of DOAC-associated intracranial hemorrhage. J Thromb Thrombol. 2023;55(1):149–55. https://doi.org/10.1007/s11239-022-02715-4.

Article  CAS  Google Scholar 

Vestal ML, Hodulik K, Mando-Vandrick J, James ML, Ortel TL, Fuller M, Notini M, Friedland M, Welsby IJ. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis. 2022;53(1):167–75. https://doi.org/10.1007/s11239-021-02495-3.

Article  CAS  PubMed  Google Scholar 

Stevens VM, Trujillo TC, Kiser TH, MacLaren R, Reynolds PM, Mueller SW. Retrospective comparison of andexanet alfa and 4-factor prothrombin complex for reversal of factor Xa-inhibitor related bleeding. Clin Appl Thromb Hemost. 2021. https://doi.org/10.1177/10760296211039020.

Article  PubMed  PubMed Central  Google Scholar 

Sadek E, Curtiss W, Andrews J, Hecht J. Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries. Emerg Med J. 2024;41(3):162–7. https://doi.org/10.1136/emermed-2023-213229.

Article  PubMed  Google Scholar 

Irizarry-Gatell VM, Bacchus MW, De Leo EK, Zhang Y, Lagasse CA, Khanna AY, Harris NS, Zumberg MS. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage. Blood Coagul Fibrinol. 2024;35(3):94–100. https://doi.org/10.1097/MBC.0000000000001279.

Article  CAS  Google Scholar 

Lipski M, Pasciolla S, Wojcik K, Jankowitz B, Igneri LA. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage. J Thromb Thrombolysis. 2023;55(3):519–26. https://doi.org/10.1007/s11239-022-02752-z.

Article  CAS